No significant clinical trials on Diabetes released at the meeting. Many clinical trials in progress. New classes of drugs are available. Commonly DPP4 inhibitors, Januvia, Onglyza, Galvus and others to follow. Oral agents with no morbility and mortality data to date.
There will be six available as early as 2013 in North America. All have same mode of action in the gut, but differ with dosing, price and side effects. Newer ones will have no renal issues at lower EGFR’s but generally those patients will be older and probably in the public reimbursement sector.
Sep 23 2011
conference 2011
Most significant trial to be released was the ARISTOLE trial, concurrently published in N.E.J.M. Apixaban from BMS is a factor X inhibitor.
Sep 19 2011
Recently I attended the European Society of Hypertension meeting June 17-20 in Milan, Italy. This area tends to be a major source of clinical trials in HTN and cardiovascular disease.
Jul 13 2011
European Calcified Tissue Society and International Bone & Mineral
Society
May 30 2011
